Sphingotec Announces Launch of Blood Test for Breast Cancer Prediction
Published: Jan 02, 2013
HENNIGSDORF, Germany, Jan. 2, 2013 /PRNewswire/ -- Sphingotec GmbH announced today that it will launch a blood test for the early prediction of breast cancer in women. The test will be available in Europe beginning in the second quarter of 2013. sphingotest® pro-NT is a simple blood test for the determination of proneurotensin (pro-NT). sphingotest® pro-NT detects the release of the satiety hormone neurotensin and is applicable to all female individuals, regardless of genetic predispositions. It shows great promise as a starting point for the prevention of breast cancer.
In 2010, breast cancer was diagnosed for 1.6 million patients worldwide. Breast cancer is the most frequent form of cancer in women.
The Journal of the American Medical Association (JAMA), a highly ranked peer-reviewed journal, recently published solid data demonstrating that determination of proneurotensin levels offers a substantial advantage in prediction of breast cancer (O. Melander et al, Plasma Pro-Neurotensin Independently Predicts Cardiometabolic Diseases, Breast Cancer, and Death In Women, Journal of the American Medical Association, Vol. 308, No. 14, pp. 1469- 1475, October 10, 2012).
"Sphingotec will offer a simple blood test that can be used by gynecologists, family doctors and clinical laboratories for women to quantify their individual risk to develop breast cancer," said Dr. Andreas Bergmann, CEO of Sphingotec GmbH. "We are confident this test will impact current prevention and early recognition programs for breast cancer and ultimately breast cancer incidence as well."
Neurotensin is a satiety hormone, released in gastrointestinal tract. The major stimulus for neurotensin production is fat. Breast cancer cell growth is stimulated by neurotensin. Since neurotensin is a very unstable peptide, Sphingotec uses the stable precursor hormone proneurotensin as a surrogate biomarker for neurotensin. High levels of proneurotensin correspond with a three-fold risk of developing breast cancer or a recurrence of breast cancer.
Proneurotensin is the subject of several ongoing US-based and European-based studies. The goal of further investigations is the discovery of appropriate interventions (e.g, a low-fat diet) in females at high risk.
About Sphingotec GmbH:
Sphingotec GmbH aims to reduce incidence of severe diseases like cancer and diabetes by identification of susceptibility factors. Sphingotec GmbH explores biomarkers that are susceptibility factors for the development of severe diseases and provides starting points for prevention strategies.
Sphingotec GmbH is a biotechnology company located in Hennigsdorf, Germany. The company was founded in 2002.
SOURCE Sphingotec GmbH